Companies › Kyowa Kirin
10 active drug programs in 11 registered trials: 7 Phase 1, 3 Phase 2, 1 Phase 3; Oncology, Ophthalmology, Metabolic and endocrine, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KK8398 Unclear - code-named drug for achondroplasia | – | Phase 3 | Achondroplasia | May 2029 |
| KHK4951 Kallikrein-bradykinin pathway inhibitor | KLKB1 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME) | Nov 2026 |
| Zandelisib (ME-401) PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma | May 2028 |
| KK2430 | – | Phase 1 | Hematologic Neoplasms | Apr 2027 |
| KK3910 | – | Phase 1 | Healthy Volunteers Essential Hypertension | Dec 2027 |
| KK2223 | – | Phase 1 | T-cell NHL (PTCL or CTCL) | Mar 2029 |
| KK2269 | – | Phase 1 | Advanced Solid Tumor | Mar 2029 |
| KK2260 | – | Phase 1 | Advanced or Metastatic Solid Tumors | Oct 2029 |
| KK8123 FGF23 inhibitor | – | Phase 1 | X-linked Hypophosphatemia | Jun 2030 |
| KK2845 | – | Phase 1 | Relapsed or Refractory AML and Other Hematologic Malignancies | Nov 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06116890 | KHK4951 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Jun 2026 |
| NCT06116916 | KHK4951 | Phase 2 | Diabetic Macular Edema (DME) | Ophthalmology | Nov 2026 |
| NCT07629726 | KK2430 | Phase 1 | Hematologic Neoplasms | Oncology | Apr 2027 |
| NCT06823947 | KK3910 | Phase 1 | Healthy Volunteers Essential Hypertension | Cardiovascular | Dec 2027 |
| NCT04533581 | Zandelisib (ME-401) | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma | Oncology | May 2028 |
| NCT07192471 | KK2223 | Phase 1 | T-cell NHL (PTCL or CTCL) | Oncology | Mar 2029 |
| NCT06266299 | KK2269 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2029 |
| NCT06926491 | KK8398 | Phase 3 | Achondroplasia | Other | May 2029 |
| NCT06248411 | KK2260 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Oct 2029 |
| NCT06525636 | KK8123 | Phase 1 | X-linked Hypophosphatemia | Metabolic and endocrine | Jun 2030 |
| NCT06812104 | KK2845 | Phase 1 | Relapsed or Refractory AML and Other Hematologic Malignancies | Oncology | Nov 2031 |
Minghui Pharmaceutical (Hangzhou) Abbisko Therapeutics Shandong Boan Biotechnology DualityBio Rhizen Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.